Deltanoid Pharmaceuticals Inc.
This article was originally published in Start Up
The University of Wisconsin - Madison spin-off is modifying the vitamin D molecule to enhance its bone building activity for the treatment of osteoporosis.
You may also be interested in...
A discovery of the mechanism behind rare genetic condition sclerosteosis led to some new insights about bone growth. OsteoGeneX has now set out to discover small molecules that could inhibit the sclerostin pathway in a variety of potential applications including increasing bone growth in osteoporosis patients, spinal fusion and fracture repair.
Rotterdam-based Therosteon is developing therapeutics for bone diseases including osteoporosis, osteoarthritis, and bone metastasis using its OsteoBLAST drug discovery platform, developed by company founder and chief scientific officer, Hans van Leeuwen.
To some, the osteoporosis space may seem crowded with Big Pharma and Big Biotech drugs already on the market and more waiting in the wings. But it's a huge market with many unmet needs, offering start-ups an opportunity to develop even better, safer, more convenient drugs. In this issue we profile four emerging companies that are intent on creating novel bone-building, not just bone-preserving, drugs for the osteoporosis market.